ResearchHub

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

Home Search Network Library Log in

ResearchHubLoading navigation…

Loading ResearchHub…

ResearchHub

Research, connected

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

Home Search Network Library Log in

ResearchHub

Research, connected

ResearchGate

TikTok

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

PDFHuB HubStor

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Cited by — Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma | ResearchHub - ResearchHub

Research graph

Cited by

Admitted local publications that cite Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.

CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma

2026 · crossref-doi · confidence 1